weight loss, compounding and Food and Drug Administration

Ending of US weight-loss drug shortages prompts compounder complaints
Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US, according to the US Food and Drug Administration (FDA). That means that compounding pharmacies and outsourcing facilities that had been legitimately preparing their own versions of the drugs will no longer be permitted to do so.
Compound versions of some weight loss drugs to be restricted
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for weight loss, as is permissible by the FDA.
Weight-loss drug battle: Who are the latest players involved
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly diving into the opportunity to make anti-obesity products. This article looks into key players in the arena.
Public health group warns about fake weight loss drugs
As weight loss drugs continue to grow in popularity in the U.S., some health leaders are warning about fake drugs on the market. Drugs like Zepbound, Ozempic, Mounjaro and
Compound versions of weight loss drugs will no longer be available, FDA rules
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.
US FDA to hold off action on weight-loss drug copies pending court ruling
The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...
UConn gene discovery moves closer to treating neuromuscular disease, holds promise for weight loss
The challenge of the obesity epidemic is widespread and one that even pediatricians face constantly,” a Connecticut doctor ...
Ozempic vs Metformin For Weight Loss: Which Is Best for Me?
The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...
Novo Nordisk Drops Price of Weight-Loss Drug Wegovy for Some Patients Paying Out of Pocket
Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying out of pocket.
Novo Nordisk Joins Legal Battle Over Weight Loss Drug Shortage
Novo Nordisk A/S can intervene in a lawsuit between the FDA and drug compounders over whether its blockbuster drugs Wegovy ...
C&EN7d
Good old pills vie for weight-loss market
The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Medscape7d
As Trump Administration Probes Long-Approved Medications, Could FDA Revoke Approvals?
A new federal commission will ‘investigate’ decades-old mental health as well as weight loss drugs, prompting concerns from ...